847 related articles for article (PubMed ID: 27658522)
1. Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP).
Lin DH; Lucas E; Murimi IB; Jackson K; Baier M; Frattaroli S; Gielen AC; Moyo P; Simoni-Wastila L; Alexander GC
Addiction; 2017 Feb; 112(2):311-319. PubMed ID: 27658522
[TBL] [Abstract][Full Text] [Related]
2. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain.
Lin HC; Wang Z; Boyd C; Simoni-Wastila L; Buu A
Addict Behav; 2018 Jan; 76():348-354. PubMed ID: 28898808
[TBL] [Abstract][Full Text] [Related]
3. Variations in prescription drug monitoring program use by prescriber specialty.
Sun BC; Lupulescu-Mann N; Charlesworth CJ; Kim H; Hartung DM; Deyo RA; John McConnell K
J Subst Abuse Treat; 2018 Nov; 94():35-40. PubMed ID: 30243415
[TBL] [Abstract][Full Text] [Related]
4. Trends in Florida's Prescription Drug Monitoring Program registration and utilization: Implications for increasing voluntary use.
Delcher C; Wang Y; Young HW; Goldberger BA; Schmidt S; Reisfield GM
J Opioid Manag; 2017; 13(5):283-289. PubMed ID: 29199394
[TBL] [Abstract][Full Text] [Related]
5. Provider Prescription Drug Monitoring Program Utilization and Self-Auditing-A Pilot Study.
Brown WC; Whitted K
J Dr Nurs Pract; 2020 Jul; 13(2):142-147. PubMed ID: 32817503
[TBL] [Abstract][Full Text] [Related]
6. Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US States.
Moyo P; Simoni-Wastila L; Griffin BA; Onukwugha E; Harrington D; Alexander GC; Palumbo F
Addiction; 2017 Oct; 112(10):1784-1796. PubMed ID: 28498498
[TBL] [Abstract][Full Text] [Related]
7. Interstate data sharing of prescription drug monitoring programs and associated opioid prescriptions among patients with non-cancer chronic pain.
Lin HC; Wang Z; Simoni-Wastila L; Boyd C; Buu A
Prev Med; 2019 Jan; 118():59-65. PubMed ID: 30316875
[TBL] [Abstract][Full Text] [Related]
8. Physicians' Perspectives Regarding Prescription Drug Monitoring Program Use Within the Department of Veterans Affairs: a Multi-State Qualitative Study.
Radomski TR; Bixler FR; Zickmund SL; Roman KM; Thorpe CT; Hale JA; Sileanu FE; Hausmann LRM; Thorpe JM; Suda KJ; Stroupe KT; Gordon AJ; Good CB; Fine MJ; Gellad WF
J Gen Intern Med; 2018 Aug; 33(8):1253-1259. PubMed ID: 29520747
[TBL] [Abstract][Full Text] [Related]
9. Association of the Use of a Mandatory Prescription Drug Monitoring Program With Prescribing Practices for Patients Undergoing Elective Surgery.
Stucke RS; Kelly JL; Mathis KA; Hill MV; Barth RJ
JAMA Surg; 2018 Dec; 153(12):1105-1110. PubMed ID: 30140927
[TBL] [Abstract][Full Text] [Related]
10. Prescription Drug Monitoring Program Use: National Dental PBRN Results.
McCauley JL; Gilbert GH; Cochran DL; Gordan VV; Leite RS; Fillingim RB; Brady KT;
JDR Clin Trans Res; 2019 Apr; 4(2):178-186. PubMed ID: 30931705
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Prescription Drug Monitoring Programs and Prescribing Guidelines on Emergency Department Opioid Prescribing: A Multi-Center Survey.
Pomerleau AC; Nelson LS; Hoppe JA; Salzman M; Weiss PS; Perrone J
Pain Med; 2017 May; 18(5):889-897. PubMed ID: 26995800
[TBL] [Abstract][Full Text] [Related]
12. Impact evaluation of a brief online training module on physician use of the Maryland, USA, Prescription Drug Monitoring Program.
Adenaiye OO; Zirpoli JB; Tan M; Day BF; Bolaji O; Mitchell CS; Cloeren M
PLoS One; 2022; 17(8):e0272217. PubMed ID: 35944051
[TBL] [Abstract][Full Text] [Related]
13. Prescription drug monitoring program design and function: A qualitative analysis.
Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC
Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492
[TBL] [Abstract][Full Text] [Related]
14. Prescribing practices, knowledge, and use of prescription drug monitoring programs (PDMP) by a national sample of medical toxicologists, 2012.
Perrone J; DeRoos FJ; Nelson LS
J Med Toxicol; 2012 Dec; 8(4):341-52. PubMed ID: 22895794
[TBL] [Abstract][Full Text] [Related]
15. Association of Prescription Drug Monitoring Program Use With Opioid Prescribing and Health Outcomes: A Comparison of Program Users and Nonusers.
Deyo RA; Hallvik SE; Hildebran C; Marino M; Springer R; Irvine JM; O'Kane N; Van Otterloo J; Wright DA; Leichtling G; Millet LM; Carson J; Wakeland W; McCarty D
J Pain; 2018 Feb; 19(2):166-177. PubMed ID: 29054493
[TBL] [Abstract][Full Text] [Related]
16. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study.
Freeman PR; Curran GM; Drummond KL; Martin BC; Teeter BS; Bradley K; Schoenberg N; Edlund MJ
Res Social Adm Pharm; 2019 Jun; 15(6):754-760. PubMed ID: 30243575
[TBL] [Abstract][Full Text] [Related]
17. Mandatory Review of Prescription Drug Monitoring Program Before Issuance of a Controlled Substance Results in Overall Reduction of Prescriptions Including Opioids and Benzodiazepines.
Manders L; Abd-Elsayed A
Pain Physician; 2020 Jun; 23(3):299-304. PubMed ID: 32517396
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Florida physicians' knowledge and attitudes toward accessing the state prescription drug monitoring program as a prescribing tool.
Gershman JA; Gershman JA; Fass AD; Popovici I
Pain Med; 2014 Dec; 15(12):2013-9. PubMed ID: 24931295
[TBL] [Abstract][Full Text] [Related]
19. Prescription Drug Monitoring Programs Produce a Limited Impact on Painkiller Prescribing in Medicare Part D.
Yarbrough CR
Health Serv Res; 2018 Apr; 53(2):671-689. PubMed ID: 28101955
[TBL] [Abstract][Full Text] [Related]
20. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
